SavedAdd your journal

Journals / Türk Biyokimya Dergisi / 2017 / Cilt: 42 - Sayı: 5

Akciğer kanserli hastalarda serum ve doku vasküler endotelyal büyüme faktörü, anjiyopoietin-1 ve anjiyopoietin-2 düzeyleri ile anjiyogenezin klinikopatolojik özelliklere göre değerlendirilmesi

Evaluation of angiogenesis with serum and tissue vascular endothelial growth factor, angiopoietin-1 and angiopoietin-2 levels in relation to clinicopathological features in lung cancer patients

Merve AKIŞ
Nezih ÖZDEMİR
Melis KANT
Nurhilal YUSUFOĞLU
Aydın ŞANLI
Pages
527–533
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This finding might be the basis for therapeutic strategies against lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate serum and tissue levels of vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) and to evaluate correlations between serum and tissue parameters with respect to clinicopathological features in patients with lung cancer.
📊
Key Findings & Data:Methods: The study was conducted on 34 patients with stage I-IV primary lung cancer and 32 healthy controls Preoperative serum, tumor and matched normal tissue VEGF, Ang-1 and Ang-2 levels were determined with ELISA.
💡
Conclusion & Impact:This finding might be the basis for therapeutic strategies against lung cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate serum and tissue levels of vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) and to evaluate correlations between serum and tissue parameters with respect to clinicopathological features in patients with lung cancer. Methods: The study was conducted on 34 patients with stage I-IV primary lung cancer and 32 healthy controls Preoperative serum, tumor and matched normal tissue VEGF, Ang-1 and Ang-2 levels were determined with ELISA. Results: Serum Ang-2 levels were significantly increased in lung cancer patients (p < 0.001). VEGF levels were significantly higher in tumor tissue than in matched normal tissue (p < 0.001). Ang-1 and Ang-2 levels were significantly higher in normal tissue than in tumor tissue (p < 0.001). A significant negative correlation was found between normal lung tissue Ang-2 and serum VEGF levels (r = − 0.400, p = 0.019). A significant correlation was observed between serum and lung tissue Ang-2 levels (r = 0.397, p = 0.020). Conclusion: This study clearly demonstrated that VEGF, Ang-1 and Ang-2 are all involved in lung cancer process. This was the first study to show a correlation between serum and tissue levels of Ang-2 in lung cancer. This finding might be the basis for therapeutic strategies against lung cancer.

Özet

Amaç: Bu çalışmanın amacı akciğer kanserli hastaların serum ve dokularında VEGF, anjiyopoietin-1 (Ang-1) and anjiyopoietin-2 (Ang-2) düzeylerinin belirlenmesi ve bu faktörlerin klinikopatolojik parametreler ile ilişkilerinin araştırılmasıdır.Yöntem: Bu çalışma tümör evresi I-IV arasında olan 34 primer akciğer kanseri hastası ve 32 sağlıklı gönüllü ile gerçekleştirildi. Hastalardan operasyon öncesinde alınan venöz kan, operasyon sırasında alınan tümör ve eşlenik normal akciğer dokusunda VEGF, Ang-1 ve Ang-2 düzeyleri ELISA yöntemi ile ölçüldü.Bulgular: Serum Ang-2 düzeyleri akciğer hastalarında anlamlı olarak yüksek bulundu (p < 0.001). VEGF düzeylerinin tümör dokuda eşlenik normal dokuya göre anlamlı olarak yüksek olduğu gözlendi (p < 0.001). Ang-1 and Ang-2 düzeyleri eşlenik normal dokuda tümör dokuya göre anlamlı yüksek bulundu (p < 0.001). Normal akciğer dokusunda Ang-2 düzeyleri ile serum VEGF düzeyleri arasında anlamlı negatif korelasyon olduğu belirlendi (r = - 0.400, p = 0.019). Serum Ang-2 ile akciğer dokusunda Ang-2 düzeyleri arasında negatif korelasyon olduğu gözlendi (r = 0.397, p = 0.020).Sonuç: Bu çalışma VEGF, Ang-1 and Ang-2?nin akciğer kanserinde rol oynadığını açıkca ortaya koymaktadır. Serum ve doku Ang-2 düzeyleri arasındaki anlamlı korelasyon ilk kez bu çalışma ile gösterilmiştir. Bu bulgu akciğer kanseri için tedavi statejilerinin belirlenmesinde temel oluşturabilir

🔖

Cite This Article

AKIŞ, M., ÖZDEMİR, N., KANT, M., YUSUFOĞLU, N., ŞANLI, A. (2022). Akciğer kanserli hastalarda serum ve doku vasküler endotelyal büyüme faktörü, anjiyopoietin-1 ve anjiyopoietin-2 düzeyleri ile anjiyogenezin klinikopatolojik özelliklere göre değerlendirilmesi. Türk Biyokimya Dergisi, Cilt: 42 - Sayı: 5, 527–533. https://ajindex.com/articles/613816

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. American Cancer Society. Cancer facts & figures 2014. Cancer Facts Fig 2014:1–72
  2. Kanodra NM, Silvestri GA, Tanner NT. Screening and early detection efforts in lung cancer. Cancer 2015;121:1347–56
  3. Naumnik W, Naumnik B, Niewiarowska K, Ossolinska M, Chyczewska E. Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. Adv Exp Med Biol 2013;788:341–8
  4. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–4
  5. Cox G, Jones JL, Walker RA, Steward WP, O’Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer 2000;27:81–100
  6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–64
  7. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–8
  8. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242–8
  9. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55–60
  10. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660–8
  11. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2–10
  12. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124–9
  13. Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett 2013;328:18–26
  14. Travis WD, Brambilla E, Müller-hermelink HK, Harris CC. Pathology & genetics tumours of the lung, pleura, thymus and heart. In: W.D. Travis, Ed. World Health Organization Classification of Tumours WHO Classification. Lyon: IARC/Press, 2004:9–122
  15. Siegel R, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29
  16. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740–801
  17. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 1998;18